Central Garden & Pet enters the back half of fiscal 2026 as a reshaped mid-cap consumer products conglomerate, having divested its lower-margin pet distribution business in April, acquired Champion animal-health assets in December, and announced a defining purchase of Germany-based TRIXIE for up to €400M. The combined effect is a cleaner portfolio biased toward branded consumables with higher gross margin, a smaller, more focused asset base in pet and garden, and an explicit pivot from low-margin distribution toward European pet specialty. Q3 FY2026 results reflect the in-flight transition rather than the steady-state outcome. Reported net sales of $882M fell 8.2% from the prior-year quarter, an optics problem that overstates operational deterioration because the divested distribution business contributed the entire revenue decline. Organic growth, which strips out M&A and exit effects, expanded 2.4%, with the Garden segment delivering a 2.9% increase and the Pet segment holding flat ex-divestiture.
The narrative for investors centers on three pillars: portfolio simplification as a margin lever, the TRIXIE transaction as a strategic step-up, and capital allocation discipline under a leveraged balance sheet. Cost and simplicity initiatives lifted gross margin in both segments, the divestiture removed the lowest-margin revenue line, and management repurchased roughly 0.8M shares at $28.55 in the quarter, a measured buyback pace consistent with preserving flexibility for the pending European deal. Total debt of roughly $1,193M sits against trailing EBITDA in the high three-hundred-million range. The resulting leverage near 3.5x remains manageable but elevated for a consumer staples issuer. The bear case rests on integration risk at TRIXIE, ongoing garden-segment cyclicality, and continued private-label pressure in pet. The bull case rests on margin expansion compounding through fiscal 2027 as the cleaner portfolio annualizes and TRIXIE contributes its first full year.
Valuation at $36.64 places the stock near 13.6x trailing earnings. The forward P/E sits near 11.7x, and the price-to-sales multiple lands close to 0.7x. The combination reads as a discount to diversified branded peer multiples, which is fair compensation for portfolio transition risk rather than structural impairment.